From the Guidelines
The recommended treatment for asthma involves a stepwise approach tailored to symptom severity, with inhaled corticosteroids (ICS) forming the cornerstone of treatment for persistent asthma, as supported by the most recent and highest quality study 1. For mild intermittent asthma, short-acting beta-agonists (SABAs) like albuterol (2 puffs every 4-6 hours as needed) provide quick symptom relief.
- Key considerations in asthma management include:
- The use of controller medications, such as ICS, long-acting beta agonists (LABAs), and leukotriene receptor antagonists, for persistent asthma.
- Combining LABAs and ICS for patients whose asthma is not adequately controlled with ICS alone, as this combination is effective and safe 1.
- The importance of patient education on proper inhaler technique, trigger avoidance, and the development of an asthma action plan.
- As severity increases, combination therapy with ICS plus LABAs like fluticasone/salmeterol (Advair) or budesonide/formoterol (Symbicort) is recommended, based on the evidence from 1 and 1.
- For severe asthma, additional options include leukotriene modifiers (montelukast 10mg daily), tiotropium, or biologics like omalizumab for allergic asthma, as suggested by 1 and 1. Regular follow-up is essential to adjust treatment based on symptom control, ensuring the best possible outcomes in terms of morbidity, mortality, and quality of life.
From the FDA Drug Label
Wixela Inhub® is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: • Twice-daily treatment of asthma in patients aged 4 years and older. For oral inhalation only. • Treatment of asthma in patients aged 12 years and older: 1 inhalation of Wixela Inhub® 100/50, Wixela Inhub® 250/50, or Wixela Inhub® 500/50 twice daily. • Treatment of asthma in patients aged 4 to 11 years: 1 inhalation of Wixela Inhub® 100/50 twice daily.
Tratamiento recomendado para el asma: El tratamiento recomendado para el asma es el uso de Wixela Inhub®, que es un producto combinado que contiene un corticosteroide y un agonista beta2-adrenérgico de acción prolongada (LABA). La dosis recomendada es de 1 inhalación de Wixela Inhub® 100/50, Wixela Inhub® 250/50 o Wixela Inhub® 500/50 dos veces al día para pacientes de 12 años o más, y 1 inhalación de Wixela Inhub® 100/50 dos veces al día para pacientes de 4 a 11 años 2.
- Pacientes de 12 años o más: 1 inhalación de Wixela Inhub® 100/50, Wixela Inhub® 250/50 o Wixela Inhub® 500/50 dos veces al día.
- Pacientes de 4 a 11 años: 1 inhalación de Wixela Inhub® 100/50 dos veces al día.
From the Research
Astma Behandling
Astma er en kronisk sygdom, der kræver regelmæssig behandling for at kontrollere symptomerne.
- Behandlingen afhænger af sværhedsgraden af astma og kan inkludere inhalationsterapi, medicin og livsstilsændringer.
Anbefalet Behandling
Ifølge 3, er inhalede corticosteroider (ICS) anbefalet som førstevalgsbehandling for persisterende astma.
- ICS kan være effektive i at reducere inflammation og forbedre lungefunktionen.
- Studier har vist, at kombinationen af ICS og langtidsvirkende beta-agonister (LABA) kan være mere effektiv end ICS alene i at kontrollere astmasymptomer 4, 5, 6.
Kombinationsbehandling
Kombinationsbehandling med ICS og LABA kan være en effektiv behandling for astma, da den kombinerer anti-inflammatoriske og bronkodilatoriske effekter.
- Studier har vist, at denne kombination kan reducere exacerbationer, forbedre lungefunktionen og forbedre astmakontrol 4, 5, 6.
- En studie fandt, at kombinationsbehandling med budesonid og formoterol var mere effektiv end salmeterol og flutikason i at reducere hospitalisationer og exacerbationer 4.
Behandling af Mild Astma
For personer med mild astma, kan en kombinationsinhalator med en fast dosis beta-agonist og steroid være en effektiv behandling.
- En studie fandt, at denne behandling kunne reducere exacerbationer og hospitalisationer sammenlignet med behandling med kun beta-agonist eller steroid alene 7.
- Behandlingen kan også reducere behovet for systemiske steroider og kan være lige så effektiv som regelmæssig steroidbehandling i at kontrollere astmasymptomer 7.